You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

JAK Inhibitors in Myelofibrosis: Expert Insights on Cases in Personalizing Therapy

  • Authors: Ruben A. Mesa, MD, FACP; Claire N. Harrison, DM, FRCP, FRCPath; Nikolai Podoltsev, MD, PhD
  • CME / ABIM MOC Released: 12/29/2022
  • Valid for credit through: 12/29/2023, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.25 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematology/oncology specialists and other healthcare professionals involved in the care of patients with MF.

The goal of this activity is for learners to improve their ability to diagnose and treat MF based on the latest data and the specific role of JAK inhibitors in the treatment paradigm. Through case-based learning, clinicians will be better equipped to tailor therapy for their patients and to manage adverse effects of treatment that may occur.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical trial data on JAK inhibitor use in the treatment of MF
    • JAK-STAT pathway and the mechanism of action of available JAK inhibitors
  • Have greater competence related to
    • Stratifying risk for patients with MF
    • Selecting appropriate therapy for patients with MF and cytopenias
    • Managing adverse events of MF therapies
  • Demonstrate greater confidence in their ability to
    • Individualize treatment for patients with MF


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Ruben A. Mesa, MD, FACP

    Professor of Medicine 
    Mays Family Foundation Distinguished University Presidential Chair
    Executive Director
    Mays Cancer Center at UT Health San Antonio
    MD Anderson Cancer Center
    San Antonio, Texas, United States

    Disclosures

    Ruben A. Mesa, MD, FACP, has the following relevant financial relationships:
    Consultant or advisor for: Constellation Pharmaceuticals; La Jolla Pharmaceutical Company; Novartis; Pharma Biotech; Sierra Oncology, a GSK Company
    Research funding from: AbbVie Inc.; Celgene Corporation; Constellation Pharmaceuticals; CTI BioPharma Corp; Genotech Pharma; Incyte Corporation; Promedior, Inc.; Samus Therapeutics, Inc.

  • Claire N. Harrison, DM, FRCP, FRCPath

    Professor of Haematology
    Deputy Medical Director, Research
    Guy's and St. Thomas' NHS Foundation Trust
    London, United Kingdom

    Disclosures

    Claire N. Harrison, DM, FRCP, FRCPath, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie Inc.; AOP Health; Constellation Pharmaceuticals; Galecto Biotech; Geron; Janssen; Keros Therapeutics; Promedior, Inc.; Sierra Oncology, a GSK Company
    Speaker or member of speakers bureau for: AbbVie Inc; Bristol Myers Squibb Company; Celgene Corporation; CTI BioPharma Corp; Novartis
    Research funding from: Bristol Myers Squibb Company; Celgene Corporation; Constellation Pharmaceuticals; Novartis

  • Nikolai Podoltsev, MD, PhD

    Associate Professor of Medicine (Hematology)
    Department of Medicine
    Yale School of Medicine
    New Haven, Connecticut, United States

    Disclosures

    Nikolai Podoltsev, MD, PhD has the following relevant financial relationships:
    Consultant or advisor for: AbbVie Inc.; Blueprint Medicines; Constellation Pharmaceuticals; CTI BioPharma Corp; Incyte Corporation; Novartis; PharmaEssentia
    Research funding from: AI Therapeutics; Arog Pharmaceuticals, Inc.; Astellas Pharma, Inc.; Astex Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc; Celgene Corporation; CTI BioPharma Corp; Daiichi Sankyo, Inc.; Genentech; Jazz Pharmaceuticals, Inc.; Kartos Therapeutics, Inc.; Pfizer, Inc.; Samus Therapeutics, Inc.; Sunesis Pharmaceuticals, Inc.
    Other: Independent Data Monitoring Committee: Cogent Biosciences, Inc.

Editor

  • Heather P. Friedman, MPH

    Medical Education Director, Medscape, LLC

    Disclosures

    Heather P. Friedman, MPH, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

JAK Inhibitors in Myelofibrosis: Expert Insights on Cases in Personalizing Therapy

Authors: Ruben A. Mesa, MD, FACP; Claire N. Harrison, DM, FRCP, FRCPath; Nikolai Podoltsev, MD, PhDFaculty and Disclosures

CME / ABIM MOC Released: 12/29/2022

Valid for credit through: 12/29/2023, 11:59 PM EST

processing....

Educational Impact Challenge

The goal of this activity is for learners to improve their ability to diagnose and treat MF based on the latest data and the specific role of JAK inhibitors in the treatment paradigm. Through case-based learning, clinicians will be better equipped to tailor therapy for their patients and to manage adverse effects of treatment that may occur.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print